Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

tolvaptan; cirrhotic ascites; survival rate; furosemide; primary biliary cholangitis; autoantibodies; ursodeoxycholic acid; treatment response; second line therapy; primary biliary cholangitis (PBC); primary sclerosing cholangitis (PSC); clinical trials; ursodeoxycholic acid (UDCA); Farnesoid X Receptor (FXR) agonist; Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists; liver cancer; systemic treatment; immunotherapy; real-world; unresectable hepatocellular carcinoma; cirrhosis; decompensation; bleeding; varices; survival; infection; alcoholic hepatitis; acute-on-chronic liver failure; cholangiocarcinoma; colorectal cancer metastases; hepatocellular carcinoma; liver transplantation; Milan criteria; alpha-fetoprotein; solid organ transplantation; liver injury; immunosuppressant; SARS-CoV-2; humoral response; vaccination; portal-systemic shunt; ammonia; vigilance; HBV; HDV; antivirals; functional cure; pharmacology; acute-on-chronic liver failure (ACLF); liver transplantation (LT); decompensated cirrhosis; portal hypertension; ascites; non-selective beta-blockers; TIPS; rifaximin; human albumin; statins; targeted therapy; effective hypovolemia; anti-mineralocorticoids; loop diuretics; vaptans; n/a